Spondyloarthropathies News

Emerging research suggests a link between chronic stress and the development of arthritis, including rheumatoid arthritis, according to a review published in Arthritis Care & Research.

Drug maker Gilead Sciences has announced it will no longer pursue FDA approval for its janus kinase inhibitor filgotinib in the treatment of rheumatoid arthritis, according to a company press release.

Although secukinumab performs similarly to adalimumab in patients with spondyloarthritis who failed their first biological treatment, adalimumab proved superior in those who failed multiple biologics, according to data.

Secukinumab demonstrated rapid, stained improvements in fatigue for up to 3 years among patients with ankylosing spondylitis, according to data published in Arthritis Care & Research.

Among patients with axial spondyloarthritis, disease activity surpassed other ‘key drivers’ such as enthesitis, gender and spinal mobility in explaining disability, according to data published in Arthritis Care & Research.

There were approximately 1.3 billion cases of musculoskeletal disorders worldwide in 2017, leading to 121,300 deaths and 138.7 million disability adjusted life years, according to findings published in Arthritis & Rheumatology.

Patients with autoimmune rheumatic diseases are less likely to avoid an office visit or laboratory tests due to COVID-19 and were more likely to have telehealth visits, according to a speaker at ACR Convergence 2020.

Patients with ankylosing spondylitis demonstrated rapid clinical response to tofacitinib, which produced significantly greater efficacy than placebo, but with more adverse events, according to a speaker at ACR Convergence 2020.

Tight control and treat-to-target, although cost-effective, are not superior to usual care for improving ASAS-HI scores in patients with axial spondyloarthritis, according to a speaker at ACR Convergence 2020.

Patients with systemic autoimmune rheumatic diseases who contract COVID-19 may have a higher risk for end-organ failure than those without such diseases, according to a speaker at ACR Convergence 2020.